A Danish study reported that treatment-naïve relapsing MS patients who received HET (FG, natalizumab, or alemtuzumab) as first DMT had a lower probability of first relapse and 6-month CDP compared to matched patients who received a low-/moderate-efficacy DMT (IFNβ, GA, TF, or DMF) at 4 years of follow-up [129]. The gene discussed is IFNB1; the disease is myeloid sarcoma.